title: High-dose chemotherapy followed by autologous stem cell transplantation as a first-line therapy for high-risk primary breast cancer: a meta-analysis.
abstract: OBJECTIVE
  Several trials have generated conflicting results about the results of high-dose chemotherapy followed by autologous stem cell transplantation (HDCT) for primary breast cancer. This meta-analysis summarizes the available evidence from all suitable studies.
  
  
  METHODS
  Prospective, randomized trials with HDCT as a first-line therapy for primary breast cancer were included in this meta-analysis. The primary outcome of interest for our analysis was survival (disease-free survival and overall survival); secondary endpoints included treatment-related mortality (TRM) and second (non-breast) cancers. We used a median age of 47, a PR positive rate of 50% and a premenopausal rate of 70% as cutoff values to complete the subgroup analyses, which were pre-planned according to the prepared protocol.
  
  
  RESULTS
  Fourteen trials with 5747 patients were eligible for the meta-analysis. Compared with non-HDCT, non-significant second (non-breast) cancers (RR = 1.28; 95% CI = 0.82-1.98) and higher TRM (RR = 3.42; 95% CI = 1.32-8.86) were associated with HDCT for primary breast cancer. A significant DFS benefit of HDCT was documented (HR = 0.89; 95% CI = 0.79-0.99). No difference in OS (overall survival) was found when the studies were pooled (HR = 0.91; 95% CI = 0.82-1.00, p = 0.062). In subgroup analysis, age and hormone receptor status had a significant interaction with prolonged DFS and OS.
  
  
  CONCLUSIONS
  HDCT has a benefit on DFS and OS compared to SDC in some special patients with high-risk primary breast cancer.
authors.affiliation: Department of Hematology, the Affiliated DrumTower Hospital of Nanjing University Medical School, Nanjing, People's Republic of China.
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.forename: Qiguo
authors.initials: Q
authors.lastname: Zhang
authors.forename: Rongfu
authors.initials: R
authors.lastname: Zhou
authors.forename: Bing
authors.initials: B
authors.lastname: Chen
authors.forename: Jian
authors.initials: J
authors.lastname: Ouyang
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy*; D004358:Drug Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D008875:Middle Aged; D015233:Models, Statistical; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D033581:Stem Cell Transplantation / Q000379:methods*; D014182:Transplantation, Autologous / Q000379:methods*; D016896:Treatment Outcome